Skip to content

ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome

ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01618526
Enrollment
22
Registered
2012-06-13
Start date
2012-04-30
Completion date
2015-05-31
Last updated
2015-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Dietary fibers, Butyrate, Short Chain Fatty Acids, Colon, Metabolic Syndrome

Brief summary

Dietary fibers including resistent starch, RS, and arabinoxylans, AX, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon. In this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are randomized to two types of diet intervention: a low and a high fiber diet. The participants are subjected to endoscopy before and in the end of each intervention.

Detailed description

Dietary fibers including resistent starch, RS, and arabinoxylans, AX, have been shown to have anti-inflammatory effects and to change the composition of the faecal micro flora in the colon. In this unblinded dietary intervention cross-over study 20 subjects with metabolic syndrome are subjected to two types of diet intervention: 1. a western style diet, WSD, with a low fiber content and 2. a healthy carbohydrate diet, HCD, a high fiber diet. Between the two 4-weeks diet is a wash-out period of four to eight weeks. The participants are subjected to endoscopy with tissue samples before and in the end of each intervention. Fecal and blood samples will be collected at the same time. We hypothesize that a high content of resistent starch and arabinoxylans increases colonic butyrate concentration, changes colon's mucosal immune system and the microbiota. A small pilot study will be carried out on 12 healthy volunteers in order to obtain a reference to participants with metabolic syndrome. The healthy volunteers will be subjected to an endoscopy but no dietary intervention.

Interventions

DIETARY_SUPPLEMENTWestern Style Diet

Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.

DIETARY_SUPPLEMENTHealthy Carbohydrate Diet

Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers

Sponsors

Aarhus University Hospital
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

At least 3 out of 5 following criteria: * Central obesity (Female \> 80 cm, Male \> 94 cm) * HDL cholesterol (Female \< 1,03 mmol/L, Male \< 1,29 mmol/L) * Bloodpressure (\> 130/85 mmHg) * Fasting Blood Glucose \> 5,6 mmol/L

Exclusion criteria

* Diabetes * Gastrointestinal disease * Serious liver, heart or kidney disease * Anticoagulation treatment * Anaemia * Corticosteroid treatment * Waist circumference above 130 cm * Alcohol or drug addiction * Pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Feces-short chain fatty acidsBaseline and 4 weeksConcentration of short chain fatty acids

Secondary

MeasureTime frame
A change in gut microbiome evaluated by 16 S-RNA analysisBaseline and 4 weeks
Change in Nuclear Factor-kappa B (NF-кB) described by gene expression analysis.Baseline and 4 weeks
Change in production of pro inflammatory cytokines on mucosal level (IFN-γ, TNF-α, IL-17).Baseline and 4 weeks
Change in production of regulatory cytokines on mucosal level and in peripheral blood mononuclear cell (IL-22, IL-10 TNF-β).Baseline and 4 weeks
Activation of T-cells in mucosa described by reduced expression of CD25 and CD69.Baseline and 4 weeks

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026